

Low Varicella Zoster Virus Seroprevalence Among Young Children in the Democratic Republic of the Congo

Reena H. Doshi, PhD, MPH,* Vivian H. Alfonso, PhD, MPH,* Patrick Mukadi, MD,† Nicole A. Hoff, PhD, MPH,* Sue Gerber, MPH,‡ Ado Bwaka, MD,§ Stephen G. Higgins, MS,¶ Cyrus Sinai, BS,* Brian Cowell, PhD, MS,|| Guillaume Ngoie Mwamba, MD,** Emile Okitolonda, MD, PhD,†† Jean-Jacques Muyembe-Tamfum, MD, PhD,‡‡ and Anne W. Rimoin, PhD, MPH*

Background: Varicella zoster virus (VZV) causes both varicella (chickenpox) and herpes zoster (shingles) and is associated with significant global morbidity. Most epidemiological data on VZV come from high-income countries, and to date there are limited data on the burden of VZV in Africa.

Methods: We assessed the seroprevalence of VZV antibodies among children in the Democratic Republic of Congo in collaboration with the 2013–2014 Demographic and Health Survey. Dried blood spot samples collected from children 6–59 months of age were run on Dynex™ Technologies Multiplier FLEX® chemiluminescent immunoassay platform to assess serologic response. Multivariate logistic regression was then used to determine risk factors for VZV seropositivity.

Results: Serologic and survey data were matched for 7,195 children 6–59 months of age, among whom 8% were positive and 2% indeterminate for VZV antibodies in weighted analyses. In multivariate analyses, the odds of seropositivity increased with increasing age, increasing socioeconomic status, mother's education level, rural residence, and province (South Kivu, North Kivu, Bandundu, Bas Congo had the highest odds of a positive test result compared with Kinshasa).

Conclusion: Our data suggest that VZV is circulating in DRC, and seropositivity is low among children 6–59 months. Seropositivity increased with age and varied by other sociodemographic factors, such as geographic location. This study provides the first nationally representative estimates of VZV infection among children in the DRC.

Key Words: varicella zoster virus, varicella, herpes zoster, immunization, vaccine-preventable diseases, Democratic Republic of the Congo

(*Pediatr Infect Dis J* 2018;37:138–143)

Varicella zoster virus (VZV) is the causative agent of both varicella (chickenpox) and herpes zoster (shingles), both of which occur worldwide.¹ Primary varicella infection is characterized by a vesicular rash and fever, usually presenting as a mild, self-limiting illness in children.² The most common complication in young

children is secondary bacterial infection^{3,4}; however, complications are more likely to occur in infants and adults, including pregnant women and immune-compromised individuals.^{5,6} VZV is highly contagious with secondary attack rates in susceptible populations ranging from 61 to 100 percentage^{7–11} and is typically transmitted person-to-person by direct contact with lesions or inhalation of aerosolized droplets.^{1,12}

Varicella is reported worldwide; however, population-based data are generally available from high-income countries.^{13–16} Studies conducted before widespread usage of the varicella vaccine in temperate regions suggest that more than 90% of children are immune to VZV by adolescence due to natural infection.^{17–20} Varicella remains a public health concern among countries that do not have widespread vaccination coverage: contrary to findings in developed countries with temperate climates, limited data from the developing world including Thailand^{21,22} and India¹⁶ suggest that varicella infection is less common in young children as infection tends to occur at a later age.¹³ This shift in the age of infection in tropical regions is also associated with markedly increased severity and complications such as skin infections, encephalitis, pneumonia, meningitis, and death.^{16,22,23} On the other hand, Guinea Bissau, a developing, tropical country, has a median age of infection of 4 years²⁴ and by 10 years of age, 90% of the population is infected.²⁵

The reasons for the differing age epidemiology in various climates remain poorly understood²⁴; possible reasons include properties of VZV, climate, population density, and the risk of exposure.^{22,26}

In the Democratic Republic of the Congo (DRC), varicella is not a reportable disease, thus the burden of infection remains unknown.²⁷ Therefore, in collaboration with the 2013–2014 DRC Demographic and Health Survey (DHS), we set out to obtain nationally representative, age-specific estimates of varicella infection among children 6–59 months of age.

METHODS

Study Population and Design

The DRC is the largest country in sub-Saharan Africa and the fourth most populous nation in the continent with an estimated 77.8 million inhabitants, 11.9 million of which are under the age of 5 years.²⁸ At the time of this study, the DRC was administratively divided into 11 provinces. The country lies directly on the equator with one-third of the country to the north and two-thirds to the south. In the equatorial climate of Equateur, Orientale and Maniema provinces, the climate is generally tropical and moist, whereas in Kinshasa, Bas Congo, Bandundu, Kasai Oriental, and Kasai Occidental provinces, the climate is considered tropical savanna. In the southern highlands of Katanga, the climate is humid and subtropical. The eastern highlands of North and South Kivu generally have a cooler, alpine climate. North and South Kivu have also experienced the largest security difficulties and attacks by rebel groups, but have received more humanitarian interventions.²⁹

Accepted for publication August 16, 2017.

From the *Department of Epidemiology, University of California, Los Angeles, Los Angeles, CA; †Department of Microbiology, Kinshasa School of Medicine, Kinshasa, DRC; ‡Bill and Melinda Gates Foundation, Seattle, WA; §McKing Consulting, Expanded Programme on Immunization, Kinshasa, DRC; ¶OpGen, Inc., Gaithersburg, MD; ||Department of Social and Behavioral Health, School of Rural Public Health, Texas A & M University, College Station, TX; **Programme on Immunization, Kinshasa, DRC; ††Kinshasa School of Public Health, Kinshasa, DRC; ‡‡National Institute for Biomedical (INRB), Kinshasa, DRC.

Drs. Doshi and Alfonso are co-first authors who contributed equally to this work. Supported by the Bill and Melinda Gates Foundation, Seattle, WA (grant number: OPP106668).

The authors have no conflicts of interest to disclose.

Address for correspondence: Anne Rimoin, PhD, MPH, Department of Epidemiology, UCLA Fielding School of Public Health, 650 S Charles E Young Drive, Los Angeles, CA 90095. E-mail: arimoin@ucla.edu.

Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved. ISSN: 0891-3668/18/3702-0138

DOI: 10.1097/INF.0000000000001750

From November 2013 to February 2014, the second DHS was conducted in the DRC. Using a 2-stage stratified cluster design, the survey generates nationally representative data on population health and social indices. Details on the sampling design and data collection procedures are described elsewhere.³⁰ Interviews were conducted among a nationally representative sample of 18,141 households. After parental consent, dried blood spots (DBS) were collected from children aged 6–59 months in 50% of the households selected.

All survey data were double entered from paper questionnaires to an electronic format, using the Census and Survey Processing System (U.S. Census Bureau, ICF Macro) and verified by comparison. Ethical approval was obtained at UCLA Fielding School of Public Health, the Kinshasa School of Public Health, and the Centers for Disease Control and Prevention.

Laboratory Analysis

DBS samples were extracted using a modified extraction protocol³¹ and processed at the UCLA-DRC laboratory housed at National Laboratory for Biomedical Research (INRB) in Kinshasa, DRC. A 0.25" DBS punch was extracted, shaken at room temperature in 1 ml phosphate buffered saline, 0.05% Polysorbate 20 and 5% dried milk, which represents a 1:143 fold dilution assuming 7 µl of serum per punch. The Dynex™ Technologies Multiplier FLEX® chemiluminescent immunoassay platform with a research use-only M² multiplex kit for measles, mumps, rubella, varicella-zoster virus and tetanus (MMRVT) was used to test samples for Immunoglobulin G (IgG) antibody response. Polystyrene beads coated separately with antigen to measles, mumps, rubella, varicella-zoster and tetanus were immobilized within 54-well M² assay strips with 10 beads per well and processed using a modified Dynex DS2® automated Enzyme-linked immunosorbent assay system for IgG antibody detection.

Cutoffs were calculated via receiver operating characteristic analysis to maximize agreement between four commercially available Federal Drug Administration-cleared Enzyme-linked immunosorbent assay kits³² and categorization of serologic results were as follows: < 0.18 IU/mL as negative; 0.18 to < 0.30 IU/mL as indeterminate; ≥ 0.30 IU/mL as positive. For analyses, the positive/negative cutoff for VZV IgG antibody detection was set at 0.30 IU/mL.

Statistical Analysis

Chi-square analyses were performed on the weighted sample (using survey weights) to examine sociodemographic differences by serologic test results (positive and negative for varicella-zoster antibody). Univariate logistic regression models were used to identify independent predictors of seropositivity among variables included in Table 1. Multivariable regression models were initially run with all variables; significant predictors (alpha < 0.05 were retained using backward selection). Children for whom test results were indeterminate (n = 125) were categorized as serologically positive, and in sensitivity analyses, these subjects were removed to assess the impact of their inclusion on findings. All statistical analyses were performed using SAS 9.4 (SAS Institute, Cary, NC), and maps were created using ArcGIS software version 9.3 (ESRI, Redlands, CA).

RESULTS

Among the 7,513 eligible 6–59 month olds, approximately 96% (n = 7,195) were linked to seroprevalence data and included in analyses. Among these children, 572 (8%) were positive, 6,498 (90%) were negative and 125 (2%) were indeterminate for varicella-zoster antibody (Fig. 1). Categorizing children with indeterminate results as positive and accounting for population sampling methods through the application of DHS sampling weights, a total

TABLE 1. Weighted Demographic Characteristics by Varicella-Zoster Serosurvey Result of 6–59 Month Old Respondents of the 2013–2014 DRC-DHS

Characteristic	Negative (n = 6,435), n (%)	Positive* (n = 815), n (%)	χ ² , P
Child age			
6–11 months†	798 (94)	51 (6)	
1 year	1,578 (93)	113 (7)	
2 years	1,468 (88)	193 (12)	
3 years	1,350 (87)	198 (13)	
4 years	1,241 (83)	260 (17)	< 0.0001
Child sex			
Male	3,224 (89)	410 (11)	
Female	3,211 (89)	405 (11)	0.8888
Children in household‡			
1	974 (92)	85 (8)	
2	1,357 (92)	115 (8)	
3	1,217 (88)	168 (12)	
4	1,067 (89)	137 (11)	
5 or more	1,821 (85)	310 (15)	< 0.0001
Mother's age at birth			
≤ 20 years	1,209 (92)	101 (8)	
21–25 years	1,699 (91)	175 (9)	
26–30 years	1,644 (90)	190 (10)	
31–35 years	1,040 (89)	133 (11)	
> 35 years	906 (90)	98 (10)	0.0298
Mother's highest level of education			
No education	1,274 (87)	187 (13)	
Primary	2,867 (91)	293 (9)	
Secondary/higher	2,295 (87)	335 (13)	< 0.0001
Wealth index§			
Poorest	1,503 (92)	129 (8)	
Poorer	1,555 (92)	135 (8)	
Middle	1,299 (88)	172 (12)	
Richer	1,158 (85)	198 (15)	
Richest	920 (84)	181 (16)	< 0.0001
Province			
Kinshasa	415 (87)	65 (13)	
Bandundu	1,062 (86)	170 (14)	
Bas-Congo	271 (86)	46 (14)	
Equateur	1,032 (96)	47 (4)	
Kasai-Occidental	524 (93)	38 (7)	
Kasai-Oriental	743 (93)	52 (6)	< 0.0001
Katanga	646 (86)	102 (14)	
Maniema	245 (96)	10 (4)	
Nord-Kivu	508 (83)	104 (17)	
Oriental	569 (92)	53 (8)	
Sud-Kivu	421 (76)	130 (24)	
Residence			
Urban	1,852 (85)	315 (15)	
Rural	4,583 (90)	500 (10)	< 0.0001

*Includes those who tested positive and indeterminate on Dynex M2 multiplex for varicella-zoster virus.


†Only children 6 months of age and older were invited to participate in the serosurvey.

‡Children in household is the sum of boys and girls who currently live in the household.

§Wealth index is a composite measure of a household's cumulative living standard, calculated from household ownership of selected assets (such as televisions and bicycles), materials used for housing construction and types of water access and sanitation facilities. Using principal components analysis, the DHS separates all interviewed households into five wealth quintiles.

of 815 children (11%) were positive and 6,435 (89%) negative (Table 1). Overall, children born to higher socioeconomic status and older mothers living in urban environments were more likely to test positive for VZV IgG compared with their younger, lower socioeconomic status, rural counterparts.

Furthermore, assessment of the assay response reveals an increase in seropositivity with increasing age: from 2% of 6-month olds to 19% of 59-month olds (range, 2–23%; Fig. 2). Among all



^a Those with missing sero-prevalence data include: 18 who were not present, 129 who refused participation, 120 for whom the DBS sample was not found in the database, 20 for whom the barcode to match DBS sample was not known, and 31 "others."

^b Varicella-zoster virus

FIGURE 1. Study inclusion for assessment of varicella-zoster virus seroprevalence among children 6–59 months of age, 2013–2014 DHS, Democratic Republic of Congo (unweighted). ^aThose with missing seroprevalence data include the following: 18 who were not present, 129 who refused participation, 120 for whom the DBS specimens were not found in the database, 20 for whom the barcode to match DBS specimen was not known and 31 "others." ^bVZV stands for varicella-zoster virus.

children, those living in North and South Kivu had the highest prevalence of seropositive children (17% and 24%, respectively), while Equateur and Maniema had the lowest (4% for both; Fig. 3). This pattern in serologic response according to geographic region persisted in those ≥ 1 year of age. However, among those 6–11 months of age, South Kivu and Kinshasa had the highest prevalence of positive results (18% and 11%, respectively) while North Kivu and Katanga had the lowest (< 1% and 1%, respectively). In multivariate analyses, the odds of seropositivity increased with increasing age, number of children residing in the household, wealth index and province (Table 2). Sensitivity analyses excluding indeterminate serologic results did not impact findings (data not shown).

DISCUSSION

These findings suggest that VZV is circulating in DRC with an overall seroprevalence of 8% among children 6–59 months of age. We also observed a trend of increasing seropositivity with older age and varying serologic response by geographic region (North and South Kivu have the highest prevalence of VZV-positive children). These findings provide the first nationally representative estimates of VZV infection among young children in the DRC.

Our findings of low infectivity among young children and increasing seroprevalence with older age are consistent with other studies.^{16,33} Between 2001 and 2004, the monkeypox active disease surveillance system estimated the average age of VZV infection to be 20.6 years among the 61 positive participants.³³ While the study was not nationally representative, it does suggest VZV exposure occurs at older ages. Our estimate of VZV seroprevalence among

children less than 5 years of age in the DRC is lower than other studies in tropical regions.¹⁶ However, estimates of seropositivity among young children differ significantly by country: estimates range from 16% of children 1–4 years of age in India³⁴; 24% of children 1–4 years of age in Thailand²¹; 26% of children 1–5 years of age in Malaysia³⁵; 30% of children under 5 years of age in the Philippines²³; and 35% of children 1–6 years of age in Singapore.³⁶ In a prospective study conducted in Guinea Bissau, the proportion of index cases was highest among children aged 2–9 years.²⁴ The lower seroprevalence in our study may be attributable to the younger study population, which includes children 6 months to < 5 years of age.

The overall trend in tropical regions may suggest that the greatest rate of seroconversion occurs in adolescence and adulthood,³⁷ which is concerning as infection in older ages is associated with increased rates of severe disease and complications (including skin infections, pneumonia and encephalitis) and mortality.^{13,16,38,39} Furthermore, as seroconversion more commonly occurs in adolescence or adulthood in tropical countries, a large proportion of reproductive age women may remain susceptible to VZV in pregnancy. VZV infection during pregnancy results in intrauterine infection in 25% of the cases.⁴⁰ Primary VZV infection in the first 20 weeks of gestation may result in congenital varicella syndrome, in which infected mothers pass on the virus to the fetus.⁴¹ An estimated 2% of fetuses are affected by the syndrome after maternal infection, resulting in outcomes ranging from low birth weight to more severe anomalies such as chorioretinitis, microcephaly, encephalitis, skin scarring and muscle wasting of the extremities severe




FIGURE 2. Varicella-zoster seropositivity according to age (in months) among 6–59 months old 2013–2014 DRC-DHS respondents (linear trend line in red). [full color online](#)




FIGURE 3. Varicella-zoster seropositivity by province and age among 6–59 months old 2013–2014 DRC-DHS respondents. BCD, Bas Congo; KIN, Kinshasa; BDD, Bandundu; KOC, Kasai Occidental; KOR, Kasai Oriental; EQT, Equateur; ORL, Orientale; MAN, Maniema; NKV, North Kivu; SKV, South Kivu; KTG, Katanga. [full color online](#)

anomalies.^{3,41,42} Infection during the third trimester and near delivery, in particular 5 days before or 2 days after birth, can cause severe and fatal infections in neonates.⁴³ After delivery, in utero infection is also associated with herpes zoster (shingles) in childhood.³ Therefore, additional serologic studies in older age groups will be important to evaluate the burden of VZV infection in the population and age-specific trends in virus circulation to identify vulnerable subgroups.

Moreover, the underlying reasons for varying response across provinces, in particular the low seroprevalence observed in Maniema and Equateur and the high seroprevalence observed in North and South Kivu, remain unclear. Such low rates of seroconversion may be the result of reduced viral circulation in high

ambient temperatures and humidity,⁴⁴ or a combination of other factors such as cross reactivity to other herpes viruses.⁴⁵ In South East Asia, outbreaks appear to be more common in cooler months and temperate regions,^{15,46–48} which is similar to the mountainous environment of North and South Kivu in eastern DRC. However, it is also possible that other factors such as increased crowding in homes in a cooler climate may favor transmission due to larger inoculum.¹⁶ Moreover, political instability in the east has led to large groups of internally displaced persons, and while densely populated and crowded environments facilitate VZV transmission,⁴⁹ the influx of potentially seronegative subjects may artificially decrease the prevalence in such areas.

TABLE 2. Weighted Logistic Regression of Sociodemographic Factors Associated With Varicella-Zoster Seropositivity of 6–59 Month Old 2013–2014 DRC-DHS Respondents

Characteristic	OR _{crude} (95% CI)	OR _{adjusted} [*] (95% CI)
Child age		
6–11 months†	Reference	Reference
1 year	1.11 (0.79–1.57)	1.51 (0.81–1.63)
2 years	2.06 (1.49–2.83)	2.12 (1.53–2.94)
3 years	2.28 (1.66–3.14)	2.41 (1.74–3.35)
4 years	3.27 (2.39–4.47)	3.19 (2.31–4.41)
Children in household‡		
1	Reference	Reference
2	0.97 (0.72–1.30)	0.77 (0.57–1.05)
3	1.58 (1.20–2.08)	1.20 (0.90–1.60)
4	1.47 (1.10–1.95)	1.15 (0.85–1.55)
5 or more	1.95 (1.51–2.51)	1.49 (1.14–1.96)
Mother's highest level of education		
No education	Reference	Reference
Primary	1.01 (0.83–1.22)	0.71 (0.57–0.87)
Secondary/higher	0.70 (0.59–0.83)	0.87 (0.69–1.11)
Wealth index§		
Poorest	Reference	Reference
Poorer	1.01 (0.79–1.30)	0.84 (0.64–1.08)
Middle	1.55 (1.22–1.97)	1.23 (0.95–1.59)
Richer	1.99 (1.58–2.52)	1.31 (1.00–1.73)
Richest	2.30 (1.81–2.93)	1.54 (1.06–2.23)
Province		
Kinshasa	Reference	Reference
Bandundu	1.03 (0.76–1.40)	1.95 (1.32–2.89)
Bas-Congo	1.09 (0.72–1.64)	1.80 (1.15–2.84)
Equateur	0.29 (0.20–0.43)	0.56 (0.35–0.88)
Kasai-Occidental	0.46 (0.30–0.70)	0.81 (0.50–1.30)
Kasai-Oriental	0.45 (0.31–0.66)	0.72 (0.47–1.11)
Katanga	1.02 (0.73–1.42)	1.48 (1.02–2.14)
Maniema	0.26 (0.13–0.52)	0.44 (0.21–0.92)
Nord-Kivu	1.32 (0.94–1.85)	1.97 (1.33–2.92)
Oriental	0.60 (0.41–0.88)	1.17 (0.76–1.82)
Sud-Kivu	1.98 (1.43–2.75)	3.41 (2.28–5.10)
Residence		
Rural	Reference	Reference
Urban	1.56 (1.34–1.81)	1.46 (1.15–1.85)

*Using backward selection, only significant predictors ($\alpha \leq 0.05$) were retained in the final model; predictors in adjusted model include all variables in Table 2.

†Only children 6 months of age and older were invited to participate in the serosurvey.

‡Children in household is the sum of boys and girls who currently live in the household.

§Wealth index is a composite measure of a household's cumulative living standard, calculated from household ownership of selected assets (such as televisions and bicycles), materials used for housing construction and types of water access and sanitation facilities. Using principal components analysis, the DHS separates all interviewed households into five wealth quintiles.

Additional limitations of our study include possible misclassification of serologic status. However, compared with four commercially available kits, the multiplex assay exhibited high validity for both sensitivity and specificity (sensitivity range, 89.5–100%; specificity range, 77.3–100%), making it unlikely that misclassification would significantly impact our findings. Furthermore, the cost-effectiveness of the multiplex assay was high as we were also able to evaluate the seroprevalence of antigens for mumps, measles, rubella, polio and tetanus. Additionally, we initially categorized serologically indeterminate children as positive; however, in sensitivity analyses, exclusion of these individuals did not change our results. Furthermore, the younger children in the study population may still have maternal antibodies.

There exists a safe and effective varicella vaccine, but it is only used in high-income countries.¹³ According to the WHO, varicella vaccine is not a high priority for routine introduction into a

national vaccination program.⁵⁰ While the morbidity and mortality associated with varicella is considerably lower than other VPDs, the virus still results in 140 million cases, 4.2 million hospitalizations, and 4,200 deaths annually in countries with limited access to health infrastructure.¹³ Complications can lead to significant healthcare and societal costs and cause a sizable burden for patients and caregivers; however, limited information exists on the health burden of varicella in developing countries and tropical climates where a higher proportion of cases may occur among adults. In these areas, varicella morbidity and mortality may be higher than that of developed countries.⁵¹

Additional epidemiologic information regarding VZV infection is of particular interest in DRC as the clinical presentation is similar to that of monkeypox virus, a zoonosis endemic to the Congo basin, where a steady increase in incidence has been reported since the cessation of routine smallpox immunization in 1982.⁵² Limited data available through MPX surveillance in DRC provide evidence that varicella is circulating,^{53,54} and findings suggest VZV infection is commonly mistaken for MPX in central Africa.^{33,54,55}

To our knowledge, this is the first study to provide a national estimate of VZV exposure among children. Evidence of the burden of VZV remains incomplete, and additional serologic studies in older populations will be required to better understand transmission and its public health significance in the DRC.

REFERENCES

- Gershon AA, Takahashi M, Seward JF. Varicella vaccine. In: Plotkin SA, Orenstein WA, Offit PA, eds. *Vaccine*. 6th ed. Philadelphia, PA: Elsevier Inc.; 2013:836–869.
- Heininger U, Seward JF. Varicella. *Lancet*. 2006;368:1365–1376.
- Preblud SR. Varicella: complications and costs. *Pediatrics*. 1986;78(4 Pt 2):728–735.
- Choo PW, Donahue JG, Manson JE, et al. The epidemiology of varicella and its complications. *J Infect Dis*. 1995;172:706–712.
- Preblud SR. Age-specific risks of varicella complications. *Pediatrics*. 1981;68:14–17.
- Fleisher G, Henry W, McSorley M, et al. Life-threatening complications of varicella. *Am J Dis Child*. 1981;135:896–899.
- Fairley CK, Miller E. Varicella-zoster virus epidemiology—a changing scene? *J Infect Dis*. 1996;174(suppl 3):S314–S319.
- Simpson RH. Infectiousness of communicable diseases in the household: (measles, chickenpox, and mumps). *Lancet*. 1952;260(6734):549–554.
- Ross AH. Modification of chicken pox in family contacts by administration of gamma globulin. *N Engl J Med*. 1962;267:369–376.
- Seward JF, Zhang JX, Maupin TJ, et al. Contagiousness of varicella in vaccinated cases: a household contact study. *JAMA*. 2004;292:704–708.
- Asano Y, Nakayama H, Yazaki T, et al. Protection against varicella in family contacts by immediate inoculation with live varicella vaccine. *Pediatrics*. 1977;59:3–7.
- Richardson M, Elliman D, Maguire H, et al. Evidence base of incubation periods, periods of infectiousness and exclusion policies for the control of communicable diseases in schools and preschools. *Pediatr Infect Dis J*. 2001;20:380–391.
- World Health Organization. Varicella and herpes zoster vaccines: WHO position paper, June 2014. *Weekly Epidemiologic Record*. 2014;25(89):265–288.
- Somekh E, Dalal I, Shohat T, et al. The burden of uncomplicated cases of chickenpox in Israel. *J Infect*. 2002;45:233–236.
- Balraj V, John TJ. An epidemic of varicella in rural southern India. *J Trop Med Hyg*. 1994;97:113–116.
- Lee BW. Review of varicella zoster seroepidemiology in India and Southeast Asia. *Trop Med Int Health*. 1998;3:886–890.
- Alp H, Altinkaynak S, Ertekin V, et al. Seroepidemiology of varicella-zoster virus infection in a cosmopolitan city (Erzurum) in the eastern Turkey. *Health Policy*. 2005;72:119–124.
- Wutzler P, Färber I, Wagenpfeil S, et al. Seroprevalence of varicella-zoster virus in the German population. *Vaccine*. 2001;20:121–124.

19. Gil A, González A, Dal-Ré R, et al. Prevalence of antibodies against varicella zoster, herpes simplex (types 1 and 2), hepatitis B and hepatitis A viruses among Spanish adolescents. *J Infect.* 1998;36:53–56.
20. Kang CI, Choi CM, Park TS, et al. Incidence of herpes zoster and seroprevalence of varicella-zoster virus in young adults of South Korea. *Int J Infect Dis.* 2008;12:245–247.
21. Migasena S, Simasathien S, Desakorn V, et al. Seroprevalence of varicella-zoster virus antibody in Thailand. *Int J Infect Dis.* 1997;2(1):26–30.
22. Lolekha S, Sathiphabha W, Sornchai P, et al. Effect of climatic factors and population density on varicella zoster virus epidemiology within a tropical country. *Am J Trop Med Hyg.* 2001;64:131–136.
23. Barzaga N, Roxas J, Florese R. Varicella zoster virus prevalence in metro Manila, Philippines. *JAMA (SE Asia).* 1994;274:S633–S635.
24. Poulsen A, Cabral F, Nielsen J, et al. Varicella zoster in Guinea-Bissau: intensity of exposure and severity of infection. *Pediatr Infect Dis J.* 2005;24:102–107.
25. Nichols RA, Averbeck KT, Poulsen AG, et al. Household size is critical to varicella-zoster virus transmission in the tropics despite lower viral infectivity. *Epidemics.* 2011;3:12–18.
26. Mandal BK, Mukherjee PP, Murphy C, et al. Adult susceptibility to varicella in the tropics is a rural phenomenon due to the lack of previous exposure. *J Infect Dis.* 1998;178(Suppl 1):S52–S54.
27. Organization WH. Vaccine introduction guidelines. *Adding a Vaccine to a National Immunization Programme: Decision and Implementation.* Geneva, Switzerland: World Health Organization; 2005.
28. Ministère du Plan, Ministère de la Santé Publique (MSP) and ICF International. *Democratic Republic of Congo Demographic and Health Survey 2013–14: Key Findings.* Rockville, MD: MPSMRM, MSP et ICF International; 2014.
29. Kandala NB, Madungu TP, Emina JB, et al. Malnutrition among children under the age of five in the Democratic Republic of Congo (DRC): does geographic location matter? *BMC Public Health.* 2011;11:261.
30. ICF International. *Sampling and household listing manual.* Calverton, Maryland; 2012.
31. Mercader S, Featherstone D, Bellini WJ. Comparison of available methods to elute serum from dried blood spot samples for measles serology. *J Virol Methods.* 2006;137:140–149.
32. Higgins SG. Validations of Dynex multiplexed serology panel for Measles, Mumps, Rubella, Varicella Zoster Virus and Tetanus (unpublished work). 2016.
33. Rimoin AW, Kisalu N, Kebela-Ilunga B, et al. Endemic human monkeypox, Democratic Republic of Congo, 2001–2004. *Emerg Infect Dis.* 2007;13:934–937.
34. Venkitaraman AR, Seigneurin J-M, Lenoir GM, et al. Infections due to the human herpes-viruses in Southern India: a seroepidemiological survey. *Int J Epidemiol.* 1986;15(4):561–566.
35. Malik YA, Baharin R. Prevalence of varicella zoster virus infection in Malaysia. In: *Proceeding of the 5th International Congress on the Impact of Viral Diseases in the Developing World*; 1995; Johannesburg, South Africa; 1995.
36. Fatha N, Ang LW, Goh KT. Changing seroprevalence of varicella zoster virus infection in a tropical city state, Singapore. *Int J Infect Dis.* 2014;22:73–77.
37. Sloan DS, Burlison A. Shift in age in chickenpox. *Lancet.* 1992;340:974.
38. Guess HA, Broughton DD, Melton LJ 3rd, et al. Population-based studies of varicella complications. *Pediatrics.* 1986;78(4 Pt 2):723–727.
39. Baren JM, Henneman PL, Lewis RJ. Primary varicella in adults: pneumonia, pregnancy, and hospital admission. *Ann Emerg Med.* 1996;28:165–169.
40. Paryani SG, Arvin AM. Intrauterine infection with varicella-zoster virus after maternal varicella. *N Engl J Med.* 1986;314:1542–1546.
41. Pastuszak AL, Levy M, Schick B, et al. Outcome after maternal varicella infection in the first 20 weeks of pregnancy. *N Engl J Med.* 1994;330:901–905.
42. Enders G, Miller E, Craddock-Watson J, et al. Consequences of varicella and herpes zoster in pregnancy: prospective study of 1739 cases. *Lancet.* 1994;343:1548–1551.
43. Sauerbrei A, Wutzler P. Neonatal varicella. *J Perinatol.* 2001;21:545–549.
44. Garnett GP, Cox MJ, Bundy DA, et al. The age of infection with varicella-zoster virus in St Lucia, West Indies. *Epidemiol Infect.* 1993;110:361–372.
45. Edson CM, Hosler BA, Respass RA, et al. Cross-reactivity between herpes simplex virus glycoprotein B and a 63,000-dalton varicella-zoster virus envelope glycoprotein. *J Virol.* 1985;56:333–336.
46. Basu RN, Jezek Z, Ward NA. *The Eradication of Smallpox from India: World Health Organization.* New Delhi, India: South East Asia Regional Office; 1979.
47. White EL. Ultrastructure and synaptic contacts in barrels of mouse SI cortex. *Brain Res.* 1976;105:229–251.
48. Health MoP. *Annual Epidemiological Surveillance Report.* Bangkok, Thailand: Ministry of Public Health; 1995.
49. Shimakawa Y, Camélique O, Ariyoshi K. Outbreak of chickenpox in a refugee camp of northern Thailand. *Confl Health.* 2010;4:4.
50. Varicella vaccines. *Wkly Epidemiol Rec.* World Health Organization; 1998.
51. Plotkin S, Orenstein W, Offit P. Varicella vaccines. In: *Vaccines.* 6th ed. Philadelphia, PA: Elsevier Inc.; 2012.
52. Rimoin AW, Mulembakani PM, Johnston SC, et al. Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. *Proc Natl Acad Sci U S A.* 2010;107:16262–16267.
53. Hutin YJ, Williams RJ, Malfait P, et al. Outbreak of human monkeypox, Democratic Republic of Congo, 1996 to 1997. *Emerg Infect Dis.* 2001;7:434–438.
54. Meyer H, Perrichot M, Stemmler M, et al. Outbreaks of disease suspected of being due to human monkeypox virus infection in the Democratic Republic of Congo in 2001. *J Clin Microbiol.* 2002;40:2919–2921.
55. MacNeil A, Reynolds MG, Carroll DS, et al. Monkeypox or varicella? Lessons from a rash outbreak investigation in the Republic of the Congo. *Am J Trop Med Hyg.* 2009;80:503–507.